2016
DOI: 10.1016/j.humpath.2015.11.006
|View full text |Cite
|
Sign up to set email alerts
|

Chaperone protein l-isoaspartate (d-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
16
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 18 publications
(17 citation statements)
references
References 28 publications
0
16
0
Order By: Relevance
“…The prognostic value of PCMT1 has been reported in lung cancer and breast cancer . Saito et al indicated that PCMT1 overexpression was a predictive biomarker of unfavorable prognosis for surgically resected lung adenocarcinoma . Lee et al demonstrated that the survival of breast cancer patients exhibiting higher‐expression of PCMT1 was significantly poorer than those with lower expression of PCMT1 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The prognostic value of PCMT1 has been reported in lung cancer and breast cancer . Saito et al indicated that PCMT1 overexpression was a predictive biomarker of unfavorable prognosis for surgically resected lung adenocarcinoma . Lee et al demonstrated that the survival of breast cancer patients exhibiting higher‐expression of PCMT1 was significantly poorer than those with lower expression of PCMT1 .…”
Section: Discussionmentioning
confidence: 99%
“…Human PCMT1 is 24.5 kDa monomeric enzyme that is comprised of two isoforms resulting from alternative splicing . In lung adenocarcinoma, PCMT1 expression was significantly lower in patients with stage I or preinvasive lesions than in those with stage II–IV or invasive adenocarcinoma . The expression status of PCMT1 in bladder cancer is still unknown.…”
Section: Introductionmentioning
confidence: 99%
“…Lung cancer (LC) is the leading cause of cancer‐related mortality worldwide, with lung adenocarcinoma (LUAD) being the most frequently diagnosed histological subtype . Most patients with LUAD are usually diagnosed at advanced stages and have a poor prognosis . It is therefore necessary to define new molecular biomarkers for the early diagnosis of LUAD.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, concern has increased regarding the pathogenic association between cancer and protein L-isoaspartyl (D-aspartyl) O- methyltransferase (PIMT), which functions as a chaperone for the conversion of isomerized L-isoaspartyl and D-aspartic acid residues into L–Asp [ 10 13 ]. Lapointe et al found that expression levels of PIMT are inversely correlated with stage progression in astrocytic tumors [ 10 ].…”
Section: Introductionmentioning
confidence: 99%
“…They demonstrated mutual interference between PIMT and wild-type p53 expression in vitro using various cell lines, and found that inductive expression of PIMT exerts an anti-apoptotic and carcinogenic effect by inhibiting the wild-type p53 pathway. We previously reported that strong expression of PIMT was immunohistochemically detected in approximately half of patients with lung adenocarcinoma and an independent predictor of poor prognosis for lung adenocarcinoma [ 13 ]. In addition, strong PIMT expression was correlated with higher levels of 78-kDa glucose-regulated protein (GRP78), a marker of ER stress, rather than p53 expression.…”
Section: Introductionmentioning
confidence: 99%